Noble Financial Initiates Coverage of Cosmos Health with Buy Rating
Noble Financial analyst Michael Kupinski has initiated coverage on Cosmos Health (COSM) with a buy rating and a price target of $1.40.
Stocks · News reference
Cosmos Health FY2026 Revenue expected to be more than $90.000M vs $84.300M Est
Cosmos Health (NASDAQ:COSM) FY2026 Revenue expected to be more than $90.000M vs $84.300M Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cosmos Health Expands E-Commerce and Subscription Business to Oceania
Cosmos Health Inc. has launched its e-commerce and subscription business in Australia, New Zealand, and the broader Oceania region, with sales already underway.
8-K filing — Cosmos Health Inc. (COSM)
Filed: 2026-10-22 AccNo: 0001477932-26-006396 Size: 625 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Cosmos Health Expects Q4 Sales Of ~$15M, Gross Profit Of ~$10.5M With Gross Margin Of ~70%
● Subscription revenue: approximately $11.5 million expected, from approximately $8.2 million in first orders and approximately $3.3 million in renewals● Order volume: 14,624 online checkout orders tracked as of October